Celiac Disease Research News

Stay up to date on advances in the development of alternative, non-dietary treatments in the celiac disease field. These articles from the Beyond Celiac Research News feed highlight the latest news and past milestones in the journey to find new treatments – or even a cure – for celiac disease. Note:  Prior to December 2015, Beyond Celiac was known as the National Foundation for Celiac Awareness. Learn more about the name change here.  
05/14/2013

AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease

AbbVie secures exclusive option to acquire global rights to ALV003, which has the potential to be the first therapy to treat celiac disease.

04/22/2013

ImmusanT's Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases

Celiac disease research could lend insight to other autoimmune diseases.

09/06/2012

Potential Celiac Drug Receives Fast Track Designation from FDA

Alvine Pharmaceuticals' ALV003 is being developed as a treatment for celiac disease in conjunction with a gluten-free diet.

09/04/2012

Biotech Company Initiates Clinical Trials for Celiac Disease Vaccine

ImmusanT announced the initiation of clinical trials for the investigational vaccine, Nexvax2.

08/13/2012

Clinical Trial Results Published for Potential Celiac Medication

Researchers released the clinical trial results for the investigational medication, larazotide acetate.

05/01/2012

Alba Therapeutics Recruiting Patients with Celiac Disease for a Phase 2b Clinical Trial

New questionnaire, the first of its kind, will be used to evaluate investigational compound in patients with celiac.

01/19/2012

Celiac Research Opportunity at Beth Israel Deaconess Medical Center in Boston, MA

Purpose of study is to determine safety and effectiveness of investigational medication for individuals with celiac disease.

12/13/2011

ImmusanT Raises $20 Million to Advance Celiac Disease Vaccine

Vaccine designed to allow celiac disease patients to return to normal gluten containing diet.

10/11/2011

Alvine Pharmaceuticals: Therapeutic Drug for Celiac Population Ready for Next Phase of Trial

Participants who took ALV300 had fewer symptoms and less intestinal damage than placebo group after 6-week gluten challenge.

05/10/2011

Phase 1 Clinical Trial of Celiac Disease Vaccine Shows Promising Results

Immunotherapeutic vaccine is designed to reduce the body's rejection of gluten, according to renowned researcher and NFCA Medical Advisory Board member Dr. Bob Anderson.

04/21/2011

Celiac Patients Want Alternatives to Gluten-Free Diet

Survey of 310 patients found vaccine is at top of wish list.

03/11/2011

Biotech Company Earns NIH Grant to Support Development of Oral Celiac Disease Therapeutic

Avaxia Biologics received $145,000 in funding to develop an “anti-gluten antibody.”

02/10/2011

Pharmaceutical Companies Partner in Plan to Develop Potential Celiac Treatment

Global pharmaceutical company Cephalon Inc. has signed an agreement with Alba Therapeutics regarding a potential celiac disease drug.

01/28/2011

IBD Drug May Help Treat Refractory Celiac Disease

Half of patients studied reported symptom relief within 4 weeks.

12/10/2010

NIH Board Approves Center for Translational Medicine and Therapeutics

New center will support development of new therapeutics, which bodes well for celiac treatment research.

1 2 3 4
OUR PARTNERS